loadpatents
name:-0.030887842178345
name:-0.015889883041382
name:-0.00072288513183594
BERNARDS; Rene Patent Filings

BERNARDS; Rene

Patent Applications and Registrations

Patent applications and USPTO patent grants for BERNARDS; Rene.The latest application filed is for "novel drug combinations for treatment of a carcinoma".

Company Profile
0.14.30
  • BERNARDS; Rene - Amsterdam NL
  • Bernards; Rene - Abcoude NL
  • Bernards; Rene - Alconde NL
  • Bernards; Rene - Brookline MA
  • Bernards, Rene - Leiderdorp NL
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Novel Drug Combinations For Treatment Of A Carcinoma
App 20220280499 - BERNARDS; Rene ;   et al.
2022-09-08
Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
Grant 10,864,179 - Wang , et al. December 15, 2
2020-12-15
Combinations for treatment of cancer
Grant 10,398,696 - Sun , et al. Sep
2019-09-03
Diagnosis And Prognosis Of Breast Cancer Patients
App 20180305768 - Dai; HongYue ;   et al.
2018-10-25
Histone Deacetylase Inhibitors For The Use In The Treatment Of Drug Resistant Melanoma
App 20180280324 - WANG; Liqin ;   et al.
2018-10-04
Diagnosis and prognosis of breast cancer patients
Grant 9,909,185 - Dai , et al. March 6, 2
2018-03-06
Methods And Means For Subtyping Invasive Lobular Breast Cancer
App 20180051346 - Bismeijer; Tycho ;   et al.
2018-02-22
Method and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction Pathways
App 20170292162 - Sun; Tian ;   et al.
2017-10-12
Means And Methods For Typing A Breast Cancer Patient And Assigning Therapy Based On The Typing
App 20160319367 - Bernards; Rene ;   et al.
2016-11-03
Novel Translocations In Lung Cancer
App 20160186269 - Bernards; Rene ;   et al.
2016-06-30
Combinations for treatment of cancer
App 20160022680 - SUN; Chong ;   et al.
2016-01-28
Methods And Means For Predicting Resistance To Anti-cancer Treatment
App 20150275306 - Bernards; Rene ;   et al.
2015-10-01
Combined use of PRAME inhibitors and HDAC inhibitors
Grant 8,969,544 - Bernards , et al. March 3, 2
2015-03-03
Methods And Compositions For Predicting Resistance To Anticancer Treatment
App 20140296248 - Bernards; Rene ;   et al.
2014-10-02
Methods And Compositions For Predicting Resistance To Anticancer Treatment
App 20140287931 - Bernards; Rene ;   et al.
2014-09-25
Methods and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction Pathways
App 20130302321 - Sun; Tian ;   et al.
2013-11-14
Combined Use Of Prame Inhibitors And Hdac Inhibitors
App 20130123327 - Bernards; Rene ;   et al.
2013-05-16
Diagnosis And Prognosis Of Breast Cancer Patients
App 20130116145 - Dai; HongYue ;   et al.
2013-05-09
Diagnosis And Prognosis Of Breast Cancer Patients
App 20110301048 - Dai; HongYue ;   et al.
2011-12-08
Combined use of PRAME inhibitors and HDAC inhibitors
Grant 7,928,081 - Bernards , et al. April 19, 2
2011-04-19
Diagnosis and prognosis of breast cancer patients
Grant 7,863,001 - Dai , et al. January 4, 2
2011-01-04
Involvement of Lipid Kinase, and Signal Transduction Pathway Comprising Said Lipid Kinase, in Resistance to HER2-Targeting Therapy
App 20100297624 - Berns; Katrien ;   et al.
2010-11-25
Diagnosis and prognosis of breast cancer patients
App 20090157326 - Dai; HongYue ;   et al.
2009-06-18
Diagnosis and prognosis of breast cancer patients
Grant 7,514,209 - Dai , et al. April 7, 2
2009-04-07
Combined Use of Prame Inhibitors and Hdac Inhibitors
App 20080119424 - Bernards; Rene ;   et al.
2008-05-22
Methods of assigning treatment to breast cancer patients
Grant 7,171,311 - Dai , et al. January 30, 2
2007-01-30
Modulation of deubiquitinase family members
App 20060105344 - Bernards; Rene ;   et al.
2006-05-18
Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays
Grant 7,012,128 - Bernards , et al. March 14, 2
2006-03-14
Assay for cell cycle modulators based on the modulation of cyclin d1 degradation in response to ionising radiation
App 20050181360 - Bernards, Rene ;   et al.
2005-08-18
Diagnosis and prognosis of breast cancer patients
App 20040058340 - Dai, HongYue ;   et al.
2004-03-25
Recombinant pox virus for immunization against tumor-associated antigens
Grant 6,699,475 - Panicali , et al. March 2, 2
2004-03-02
Diagnosis and prognosis of breast cancer patients
App 20030224374 - Dai, HongYue ;   et al.
2003-12-04
Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds
App 20030166167 - van Es, Helmuth ;   et al.
2003-09-04
Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds
App 20030059794 - Vogels, Ronald ;   et al.
2003-03-27
Transcription factor - E2F-5
App 20030022260 - La Thangue, Nicholas B. ;   et al.
2003-01-30
Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays
App 20020177177 - Bernards, Rene ;   et al.
2002-11-28
Transcription factor E2F-4
Grant 6,303,335 - Bernards , et al. October 16, 2
2001-10-16
Transcription factor E2F-4
Grant 6,045,999 - Bernards , et al. April 4, 2
2000-04-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed